Targeting intrinsic and extrinsic vulnerabilities for the treatment of multiple myeloma

Tekijä Anreddy, Nagaraju, Hazlehurst, Lori A
Julkaisussa J Cell Biochem (2016)

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

Tekijä Nair, Rajesh R., Tolentino, Joel, Hazlehurst, Lori A.
Julkaistu 2010

The Role of TRPC1 in Modulating Cancer Progression

Tekijä Elzamzamy, Osama M, Penner, Reinhold, Hazlehurst, Lori A
Julkaisussa Cells (2020)

Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors

Tekijä Chen, Wei-Chih, Hu, Gangqing, Hazlehurst, Lori A.
Julkaisussa Curr Opin Pharmacol (2020)

Role of STAT3 in Transformation and Drug Resistance in CML

Tekijä Nair, Rajesh R., Tolentino, Joel H., Hazlehurst, Lori A.
Julkaistu 2012

The Role of ERO1α in Modulating Cancer Progression and Immune Escape

Tekijä Johnson, Brennan D., Geldenhuys, Werner J., Hazlehurst, Lori A.
Julkaisussa J Cancer Immunol (Wilmington) (2020)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

Tekijä Chen, Wei-Chih, Kanate, Abraham S, Craig, Michael, Petros, William P, Hazlehurst, Lori A
Julkaisussa Cancer Manag Res (2017)

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

Tekijä Damiano, Jason S., Cress, Anne E., Hazlehurst, Lori A., Shtil, Alexander A., Dalton, William S.
Julkaisussa Blood (1999)

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells

Tekijä Chen, Qing, Van der Sluis, Pieter C., Boulware, David, Hazlehurst, Lori A., Dalton, William S.
Julkaistu 2005

Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma

Tekijä Elzamzamy, Osama M., Johnson, Brandon E., Chen, Wei-Chih, Hu, Gangqing, Penner, Reinhold, Hazlehurst, Lori A.
Julkaisussa Cells (2021)

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

Tekijä Bewry, Nadine N., Nair, Rajesh R., Emmons, Michael F., Boulware, David, Pinilla-Ibarz, Javier, Hazlehurst, Lori A.
Julkaistu 2008

Tipifarnib-Induced Apoptosis in Acute Myeloid Leukemia and Multiple Myeloma Cells Depends on Ca(2+) Influx through Plasma Membrane Ca(2+) Channels

Tekijä Yanamandra, Niranjan, Buzzeo, Robert W., Gabriel, Mark, Hazlehurst, Lori A., Mari, Yelenis, Beaupre, Darrin M., Cuevas, Javier
Julkaistu 2011

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML

Tekijä Nair, Rajesh R., Tolentino, Joel H., Argilagos, Raul F., Zhang, Ling, Pinilla-Ibarz, Javier, Hazlehurst, Lori A.
Julkaistu 2011

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Tekijä Shay, Gemma, Tauro, Marilena, Loiodice, Fulvio, Tortorella, Paolo, Sullivan, Daniel M., Hazlehurst, Lori A., Lynch, Conor C.
Julkaisussa Oncotarget (2017)

β1 integrin adhesion enhances IL-6 mediated STAT3 signaling in Myeloma cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

Tekijä Shain, Kenneth H., Yarde, Danielle N., Meads, Mark B., Huang, Mei, Jove, Richard, Hazlehurst, Lori A., Dalton, William S.
Julkaistu 2009

MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma

Tekijä Emmons, Michael F., Anreddy, Nagaraju, Cuevas, Javier, Steinberger, Kayla, Yang, Shengyu, McLaughlin, Mark, Silva, Ariosto, Hazlehurst, Lori A.
Julkaisussa Sci Rep (2017)

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCF(Skp2) ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas

Tekijä Lwin, Tint, Hazlehurst, Lori A., Dessureault, Sophie, Lai, Raymond, Bai, Wenlong, Sotomayor, Eduardo, Moscinski, Lynn C., Dalton, William S., Tao, Jianguo
Julkaistu 2007

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Tekijä Turner, Joel G., Marchion, Douglas C., Dawson, Jana L., Emmons, Michael F., Hazlehurst, Lori A., Washausen, Peter, Sullivan, Daniel M.
Julkaistu 2009

Acquisition of resistance towards HYD1 correlates with a reduction in cleaved alpha 4 integrin expression and a compromised CAM-DR phenotype

Tekijä Emmons, Michael F., Gebhard, Anthony W., Nair, Rajesh R., Baz, Rachid, McLaughlin, Mark, Cress, Anne E., Hazlehurst, Lori A.
Julkaistu 2011

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Tekijä Turner, Joel G., Dawson, Jana, Emmons, Michael F., Cubitt, Christopher L., Kauffman, Michael, Shacham, Sharon, Hazlehurst, Lori A., Sullivan, Daniel M.
Julkaistu 2013